As Cu­ria ex­pands, it will add API site in up­state New York; In bat­tle against food al­ler­gies, Al­ladapt to build site to prep for PhI­II tri­als

In Ju­ly, con­tract man­u­fac­tur­er AM­RI re­brand­ed as Cu­ria, and wran­gled two biotechs to aid in its move to­ward glob­al ex­pan­sion. Thurs­day, the com­pa­ny an­nounced that it will up its com­mer­cial man­u­fac­tur­ing at its Rens­se­laer, NY site.

Cu­ria will in­vest more than $35 mil­lion to dou­ble the batch-size scal­ing and pack­ag­ing op­er­a­tions, and al­low Cu­ria to man­u­fac­ture APIs for new prod­ucts.

“Our Rens­se­laer team’s his­to­ry of ex­cel­lence in de­liv­er­ing U.S.-based com­plex man­u­fac­tur­ing so­lu­tions that en­able our cus­tomers to pro­vide vi­tal treat­ments to pa­tients is re­sult­ing in in­creas­ing de­mand,” CEO John Ratliff said in a press re­lease. “Some of the life-sav­ing prod­ucts pro­duced at Rens­se­laer are high­ly com­plex, in­clud­ing crit­i­cal on­col­o­gy ther­a­peu­tics and nov­el treat­ments ad­dress­ing un­met med­ical needs. The en­gi­neer­ing and tech­nol­o­gy ad­vances we have de­signed for the site will en­hance our flex­i­bil­i­ty, ef­fi­cien­cy and scale, al­low­ing us to meet our cus­tomers’ cur­rent and fu­ture com­plex man­u­fac­tur­ing needs.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER